Search

Your search keyword '"Utriainen, Pauliina"' showing total 38 results
Start Over Author "Utriainen, Pauliina"
38 results on '"Utriainen, Pauliina"'

3. Bisphosphonate treatment for skeletal complications in paediatric cancer--Experience from a single tertiary centre.

Author

Utriainen, Pauliina, Stenberg, Jalmari E. E., Vettenranta, Kim K., and Mäkitie, Outi M.

Subjects
*STEM cell transplantation, *CHILDHOOD cancer, *CHILD patients, *VERTEBRAL fractures, *THERAPEUTIC complications, *VERTEBRAE injuries, *BONE density
Abstract

Aims: The aim was to analyse the use and safety of bisphosphonate treatment for metabolic bone complications in paediatric cancer patients. Methods: We retrospectively describe our experience with bisphosphonate treatment in 25 childhood cancer patients (aged <18 years) in a single tertiary hospital between 1999 and 2020. Results: The most common primary diagnosis was acute lymphoblastic leukaemia (n = 16) and Hodgkin lymphoma (n = 3). Eleven patients (44%) had received allogeneic stem cell transplantation and two patients autologous stem cell transplantation. Sixteen patients (64%) had been treated with radiotherapy, either total-body (n = 11) or local (n = 5). The main indication for bisphosphonates was osteoporosis with vertebral compression fractures in 13/25, osteonecrosis in 6/25 and hypercalcaemia in 2/25. The bisphosphonate treatment was started on average 13 (range 0-76) months after the diagnosis of the bone complication. Bisphosphonate treatment lasted between weeks (hypercalcaemia) to 5 years (severe osteoporosis). Mild, non-symptomatic hypophosphatemia (n = 8), hypocalcaemia (n = 6) and moderate, transient pain (n = 6) were the most common adverse effects. No severe side effects were observed even when bisphosphonates were administered concomitantly with chemotherapy. Bone mineral density significantly improved with the bisphosphonate treatment (mean lumbar spine Z-score -1.17 vs. -0.07, p < 0.001). Conclusion: Bisphosphonate treatment was well tolerated in this paediatric patient cohort. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Ennenaikainen adrenarke : yleinen, moni-ilmeinen ja hyväennusteinen kehitysvariantti

Author

Liimatta, Jani, Utriainen, Pauliina, Voutilainen, Raimo, Jääskeläinen, Jarmo, Clinicum, HUS Lasten ja nuorten sairaudet, Lastenklinikka, Helsingin yliopisto, and HUS Helsingin ja Uudenmaan sairaanhoitopiiri

Subjects
Metabolic Syndrome, Adolescent, Dehydroepiandrosterone Sulfate, Puberty, Ovary, Overweight, Lipid Metabolism, Zona Reticularis, +physiopathology, Glucose, 3123 Naisten- ja lastentaudit, Hypertension, Androgens, Quality of Life, +metabolism, Adrenarche, Female, Obesity, Growth and Development, Insulin Resistance, Child, Polycystic Ovary Syndrome
Abstract

Vertaisarvioitu. English summary

Published
2020

12. Cardiometabolic risk profile among young adult females with a history of premature adrenarche

Author

Liimatta, Jani, Utriainen, Pauliina, Laitinen, Tomi, Voutilainen, Raimo, Jääskeläinen, Jarmo, and HUS Children and Adolescents

Subjects
dehydroepiandrosterone sulfate, body composition, PRECOCIOUS PUBARCHE, INSULIN SENSITIVITY, CARDIOVASCULAR RISK, CHILDHOOD, AMERICAN, CHILDREN, metabolic syndrome, 3121 General medicine, internal medicine and other clinical medicine, insulin resistance, OBESITY, GIRLS, WEIGHT
Abstract

Context: Premature adrenarche (PA) is associated with childhood overweight and hyperinsulinemia; the long-term cardiometabolic outcome is unknown. Objective: To study cardiometabolic profile in adult women with previous PA. Design and participants: Thirty women with PA and 41 control subjects were followed from prepuberty to young adulthood. Main outcome measures: Prevalence of the metabolic syndrome (MetS) and clinical and biochemical cardiovascular risk factors. Results: There were no differences in the prevalence of MetS or in any parameters indicating dyslipidemia, hypertension, hepatosteatosis, atherosclerosis, or low-grade inflammation between the study groups. However, prevalence of insulin resistance (IR; P = 0.014) and acanthosis nigricans (P = 0.010) was higher in the PA group. Neither fasting glucose nor insulin concentrations differed between the study groups, but HbA1c [adjusted for body mass index (BMI) P = 0.011] and Homeostatic Model Assessment of Insulin Resistance (P = 0.044; BMI-adjusted P = nonsignificant) were higher in the PA group. Although BMI and fat percentage were comparable between the study groups, the PA group had higher central fat mass than the control group. In the whole study population, MetS and IR were associated with greater adult fat mass, but no prepubertal factors predicting later IR were found. Conclusion: PA does not seem to be associated with MetS, dyslipidemia, hypertension, atherosclerosis, or low-grade inflammation in young adult women. However, some women with PA may be at an increased risk of unfavorable glucose metabolism, which is associated with increased central adiposity at adult age rather than determined by prepubertal factors. Copyright (C) 2019 Endocrine Society

Published
2019

37. Inhibition of DNA methylation increases follistatin expression and secretion in the human adrenocortical cell line NCI-H295R

Author

Utriainen, Pauliina, Liu, Jianqi, Kuulasmaa, Tiina, and Voutilainen, Raimo

Abstract

Activin affects adrenocortical steroidogenesis and increases apoptosis, while follistatin (FS) acts as an activin antagonist by binding to activin, preventing attachment to its receptors. The regulation of FS expression in the adrenal cortex is poorly understood. Adrenocortical tumors often display aberrant methylation. In the present study, we investigated the effect of DNA methylation on FS mRNA expression and peptide secretion in adrenocortical cells. We treated human NCI-H295R adrenocortical cells with the methylation inhibitor 5-Aza-2′deoxycytidine (Azad; 0.1–100 μM for 1, 4 or 7 days) and measured FS mRNA expression by Northern blot and quantitative real time RT-PCR analyses as well as FS secretion by specific ELISA. Methylation-specific PCR showed decreased methylation in the FS promoter region after Azad treatment. A significant (P< 0.05) time- and dose-dependent increase in FS mRNA expression (up to 4.6-fold) and peptide secretion (up to 17.1-fold) was detected after Azad treatment. We conclude that FS gene expression and peptide secretion in NCI-H295R adrenocortical cells are regulated by DNA methylation. Thus, variable methylation in different adrenocortical tumors may influence activin bioactivity and its consequences in steroidogenesis and cell proliferation/apoptosis.

Published
2005
Full Text
View/download PDF

38. Cognitive performance in young adult women with a history of premature adrenarche.

Author

Tennilä J, Muukkonen L, Utriainen P, Voutilainen R, Jääskeläinen J, and Liimatta J

Abstract

Background: Girls with premature adrenarche (PA) mature earlier than peers and have been found to have greater symptom accounts reflecting anxiety compared to peers. It is not known, however, whether PA effects cognitive development. This longitudinal case-control cohort study aimed: (1) To investigate whether a history of PA leads to measurable changes in adulthood cognitive performance, and (2) to assess whether findings characteristic of PA girls predict adulthood cognitive performance., Methods: Twenty-seven girls with PA and 27 age-matched control girls were examined and followed from mid-childhood (mean age 7.2 years) until early adult age (18.5 years). Wechsler Adult Intelligence Scale, Fourth Edition scores were used as main outcome measure., Results: Allostatic load (AL) scores, which compile multisystem variables to reflect the overall wear and tear of the body from increased and prolonged stress, were higher in the PA group in both prepuberty and adulthood, but there were no differences in WAIS-IV results between the groups (full-scale IQ 92.7 vs. 97.5, p 0.376; no differences in separate indexes). Childhood androgen levels, glucose metabolism biomarkers, and AL scores failed to predict adulthood cognitive performance outcomes., Conclusion: The study suggests that PA does not predispose to adverse adulthood outcomes of cognitive development., Impact: The study suggests that a history of premature adrenarche (PA) does not affect cognitive performance in adult age. Childhood androgen levels and biomarkers of glucose metabolism failed to predict adulthood cognitive outcomes in this study. Allostatic load scores were elevated in the PA group both in childhood and adulthood but did not predict adulthood cognitive outcomes., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results